Canadian Society of Internal Medicine Annual Meeting 2019 Halifax, - - PowerPoint PPT Presentation

canadian society of internal medicine
SMART_READER_LITE
LIVE PREVIEW

Canadian Society of Internal Medicine Annual Meeting 2019 Halifax, - - PowerPoint PPT Presentation

Canadian Society of Internal Medicine Annual Meeting 2019 Halifax, NS Geriatrics 2019 Update: Pills and Falls Dr. Kim Babb MD FRCPC Memorial University of Newfoundland kimberly.babb@easternhealth.ca CSIM Annual Meeting 2019 The following


slide-1
SLIDE 1

Canadian Society of Internal Medicine

Annual Meeting 2019

Halifax, NS

Geriatrics 2019 Update: Pills and Falls

  • Dr. Kim Babb MD FRCPC

Memorial University of Newfoundland kimberly.babb@easternhealth.ca

slide-2
SLIDE 2

CSIM Annual Meeting 2019

The following presentation represents the views of the speaker at the time of the

  • presentation. This information is meant for educational purposes, and should not replace
  • ther sources of information or your medical judgment.

Learning Objectives

  • 1. Appreciate the overall importance of active deprescribing

in the older adult.

  • 2. Understand how failure to deprescribe may promote

frailty.

  • 3. Learn practical strategies and clinical significance of

deprescribing in the older adult.

  • 4. Identify effective fall-prevention strategies.
slide-3
SLIDE 3

CSIM Annual Meeting 2019

Conflict Disclosures

I have the following conflicts to declare:

  • Member of the Scientific Planning Committee for Core

Geriatric Experiences in Primary Care (NLMA Family Practice Renewal Program)

  • Author and speaker for the Frailty I and II programs
  • Received honoraria from Pfizer for delivering CME on

“Caring for our Elderly Patients: A Focus on OAB and AF”

slide-4
SLIDE 4

Audience Participation

Website: PollEV.com/kimbabb743 Text: KIMBABB743 to 22333 once to join

slide-5
SLIDE 5

The Case of Ed

slide-6
SLIDE 6

The Case of Ed

  • 83M referred for a cognitive assessment
  • PMHx:

1. Depression 2. Atrial fibrillation 3. TIIDM (HgA1c 6.2%) 4. HTN 5. DLP 6. OA 7. Urinary incontinence (indwelling foley for 1 month) 8. Recurrent UTIs 9. CKD (eGFR ~30%)

slide-7
SLIDE 7

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily

**warfarin recently d/c by FP secondary to falls

slide-8
SLIDE 8

Audience Poll

Q: Which statement is true?

  • a. The overall anticholinergic burden is low.
  • b. The overall anticholinergic burden is high.
  • c. Regardless of anticholinergic burden, the

medications seem reasonable, so no need to make adjustments.

  • d. I have no idea how to calculate anticholinergic

burden.

slide-9
SLIDE 9

The Case of Ed

  • Appeared frail
  • Wheelchair, unable to stand unassisted
  • BP 130/60 sitting, 98/48 standing
  • HR 78 sitting, 90 standing
  • MMSE 22/30

– 8/10 orientation, 1/5 concentration, 2/3 recall, 2/3 command

slide-10
SLIDE 10

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily

**warfarin recently d/c by FP secondary to falls

slide-11
SLIDE 11

Polypharmacy

Definition: LOTSA + MEDS

  • More medications than clinically indicated
  • Use of those carrying a high risk of adverse drug

events

  • Increasingly refers to underuse of potentially

useful medication

slide-12
SLIDE 12
slide-13
SLIDE 13

Polypharmacy

  • Polypharmacy is commonly seen in frailty

– Complex association

  • Polypharmacy can promote frailty
slide-14
SLIDE 14

Frailty

A physiologic decline in later life characterized by marked vulnerability to adverse health outcomes.

slide-15
SLIDE 15
slide-16
SLIDE 16

Frailty

slide-17
SLIDE 17
slide-18
SLIDE 18

Frailty at SCMH

17 14 26 83 86 74 20 40 60 80 100 120 7 West 7 East 4 West

Percentage of Frail Elderly Acute Care Medicine Patients SCMH

% Screen negative ( 3 or less) % Screen positive (4 or more)

80% screened vulnerable to frail 562 IM inpatients

slide-19
SLIDE 19

Frailty at SCMH

20 40 60 80 100 120 Very fit Well Managing well Vulnerable Mildly frail Moderately frail Severely frail Very severely frail Terminally ill

Clinical Frailty Scores

Total number of patients Percentage of patients

slide-20
SLIDE 20
slide-21
SLIDE 21

Polypharmacy

  • Polypharmacy is commonly seen in frailty

– Complex association

  • Response to multimorbidity
  • Can mimic geriatric syndromes
  • Multimorbidity + Geriatric syndromes  Frailty
slide-22
SLIDE 22

Polypharmacy can promote frailty

slide-23
SLIDE 23

Polypharmacy

Polypharmacy outcomes

  • Increased hospitalizations
  • Cognitive impairment
  • Functional impairment
  • Prolonged hospitalizations/readmissions
  • Poor compliance
  • Mortality
  • Falls
  • Independent risk factor for hip fracture
slide-24
SLIDE 24

Polypharmacy

  • Drug-induced events can mimic other geriatric

syndromes

– Urinary incontinence, confusion, falls – Often leads to prescribing cascade

slide-25
SLIDE 25

Prescribing Cascade

  • Arthritis

NSAID

  • HTN

CCB

  • Ankle

edema

Diuretic

  • Incontinence

Bladder antimuscarinic

slide-26
SLIDE 26

http://www.slideshare.net/prashantshukla927/polypharmacy-57404596

slide-27
SLIDE 27

Why Deprescribe?

Polypharmacy outcomes

  • Increased hospitalizations
  • Falls
  • Cognitive impairment
  • Functional impairment
  • Prolonged hospitalizations/readmissions
  • Poor compliance
  • Mortality
  • Frailty
slide-28
SLIDE 28

Why Deprescribe?

  • Estimates noncompliance in the elderly vary

– 40 - 75%

  • Decreased compliance with
  • 3 more more drugs
  • Dosing more than once a day
  • Side effect profile
slide-29
SLIDE 29

Why Deprescribe?

Adverse drug reactions

  • 1/3 of people taking ≥ 5 medications will have

an adverse drug reaction

– About 2/3 of these will require medical attention

American Family Physician Dec 15th, 2007 Pham and Dickman

slide-30
SLIDE 30

Deprescribing

  • Robust patients

– Mobile and functionally independent

  • Medication focus on prevention, treatment/alleviation
  • f symptoms and delay morbidity and mortality
  • Frail patients

– Less mobile, functionally dependent

  • Medication focus on maintaining function and quality
  • f life
slide-31
SLIDE 31

Deprescribing

  • A process!
  • Tapering, withdrawing, discontinuing medications
  • Often involves substitution for a safer agent
  • Goal is improving outcomes
slide-32
SLIDE 32

Deprescribing

Golden Rules:

  • Fight complacency!!!
  • The goal is NOT zero
  • One thing at a time, and that one thing slowly
  • Go slow…but GO
  • Shared decision making model
  • Think about conditions that are undertreated
slide-33
SLIDE 33

Audience Poll

Q: Which medication class is often under-prescribed in older adults?

  • a. Beta-blockers
  • b. Statins
  • c. Statins
  • d. Hypoglycemics
slide-34
SLIDE 34

Deprescribing

Challenges:

  • Clinical practice guidelines are not focused on
  • lder adults

– Rarely (if ever) focused on frailty

  • Evidence does not always inform practice
  • Generalists do not like to interfere with the

specialists medication prescribing

  • Transitions of care
slide-35
SLIDE 35

Deprescribing

  • Reasons to continue medications:

– Important indications (ex: AF, osteoporosis) – Low tolerance for symptoms/cannot tolerate tapering

  • Reasons to wean/stop medications:

– Adverse drug reactions – No indication – Treating side effect of another medication (cascade)

slide-36
SLIDE 36

Deprescribing Tools

(1) Beers Criteria

  • What not to use

(2) STOPP/START

  • Systems based approach to starting

appropriate and stopping inappropriate meds

  • “Toolkit”
slide-37
SLIDE 37

Anticholinergic Burden

  • Older adults have diminished reserved of

acetylcholine

  • Resultantly, more susceptible to adverse

effects of anticholinergic medications

– Especially cognitive effects

slide-38
SLIDE 38

Anticholinergic Burden

  • Medications can be classified based on degree
  • f anticholinergic activity

– None, low, medium, high

  • Beware the “anticholinergic burden”

– Cumulative adverse effects of overall anticholinergic “load”

slide-39
SLIDE 39

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily
slide-40
SLIDE 40

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily
slide-41
SLIDE 41

Deprescribing

My approach:

  • 1. Is the patient ready?
  • 2. Problem list/Medication list*
  • 3. Assess frailty

– Assess use of preventative medications in terminal/end stage disease

  • 4. Prescribing cascade?
  • 5. Anticholinergic burden?
  • 6. Deprescribing tools as resources (BEERS Criteria,

STOPP/START, etc)

slide-42
SLIDE 42

The Case of Ed

DIAGNOSIS MEDICATION

  • 1. Depression
  • Lorazepam 2mg po qid
  • 2. Atrial fibrillation
  • 3. TIIDM
  • Insulin NPH 16u qhs
  • Insulin R 22u breakfast, 9u lunch, 14u

supper

  • 4. HTN
  • HCTZ 12.5mg daily
  • Candesartan/HCTZ 16/12.5mg daily
  • 5. DLP
  • Simvastatin 40mg daily
  • 6. OA
  • Tylenol 650mg tid prn
  • 7. Urinary incontinence
  • Solifenacin 10mg daily
  • 8. Recurrent UTIs
  • 9. CKD
slide-43
SLIDE 43

The Case of Ed

DIAGNOSIS MEDICATION

  • 1. Depression
  • Lorazepam 2mg po qid
  • 2. Atrial fibrillation
  • 3. TIIDM
  • Insulin NPH 16u qhs
  • Insulin R 22u breakfast, 9u lunch, 14u

supper

  • 4. HTN
  • HCTZ 12.5mg daily
  • Candesartan/HCTZ 16/12.5mg daily
  • 5. DLP
  • Simvastatin 40mg daily
  • 6. OA
  • Tylenol 650mg tid prn
  • 7. Urinary incontinence
  • Solifenacin 10mg daily
  • 8. Recurrent UTIs
  • 9. CKD
slide-44
SLIDE 44

The Case of Ed

DIAGNOSIS MEDICATION

No history CAD, MI, Stroke

  • ASA 81 mg daily

No clear indication

  • Omega 3 1000mg tid

Hx constipation, poorly treated

  • Docusate sodium 100mg bid
  • Senna 2-4 tablets qhs

No clear indication, eats well

  • Multivitamin daily
  • Folic Acid 1mg daily

No clear indication, strongly anticholinergic

  • Pregabalin 75mg qhs

No hx GERD ?Prescribing cascade

  • Ranitidine 150mg bid
  • Pantoprazole 40mg daily

?Prescribing cascade

  • Mg supplement daily
slide-45
SLIDE 45

The Case of Ed

DIAGNOSIS MEDICATION

No history CAD, MI, Stroke

  • ASA 81 mg daily

No clear indication

  • Omega 3 1000mg tid

Hx constipation, poorly treated

  • Docusate sodium 100mg bid
  • Senna 2-4 tablets qhs

No clear indication, eats well

  • Multivitamin daily
  • Folic Acid 1mg daily

No clear indication

  • Pregabalin 75mg qhs

No hx GERD ?Prescribing cascade

  • Ranitidine 150mg bid
  • Pantoprazole 40mg daily

?Prescribing cascade

  • Mg supplement daily
slide-46
SLIDE 46

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily
slide-47
SLIDE 47

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily
slide-48
SLIDE 48

The Case of Ed

  • 1. Candesartan/HCTZ 16/12.5mg daily
  • 2. Simvastatin 40mg daily
  • 3. Solifenacin 10mg daily
  • 4. Insulin NPH 16u qhs
  • 5. Insulin R 22u breakfast, 9u lunch, 14u supper
  • 6. Mg supplement daily
  • 7. Senna 2-4 tablets qhs
  • 8. Lorazepam 2mg po qid
  • 9. Pregabalin 75mg qhs
  • 10. Tylenol 650mg tid prn
  • 11. Pantoprazole 40mg daily
slide-49
SLIDE 49

The Case of Ed

  • 1. Candesartan/HCTZ 16/12.5mg daily – decreased dose
  • 2. Simvastatin 40mg daily
  • 3. Solifenacin 10mg daily - weaned
  • 4. Insulin NPH 16u qhs – reduced dose
  • 5. Insulin R 22u breakfast, 9u lunch, 14u supper – reduced dose
  • 6. Mg supplement daily
  • 7. Senna 2-4 tablets qhs – increased to bid
  • 8. Lorazepam 2mg po qid – weaned after initiating SSRI
  • 9. Pregabalin 75mg qhs - weaned
  • 10. Tylenol 650mg tid prn – changed to regular
  • 11. Pantoprazole 40mg daily
slide-50
SLIDE 50

Audience Poll

Q: Would you restart his warfarin?

  • a. Yes
  • b. No
  • c. Unsure
slide-51
SLIDE 51

Audience Poll

Q: How many times per year must an older adult fall for warfarin not to be the optimal therapy for stroke prevention in atrial fibrillation?

  • a. 55
  • b. 125
  • c. 200
  • d. 295
slide-52
SLIDE 52

Clinical Pearl

The propensity to fall is NOT a contraindication to anticoagulation in older adults with atrial fibrillation.

295

slide-53
SLIDE 53

The Case of Ed

  • 1. Candesartan/HCTZ 16/12.5mg daily
  • 2. Simvastatin 40mg daily
  • 3. Insulin NPH 12u qhs
  • 4. Insulin R 18u breakfast, 5u lunch, 10u supper
  • 5. Senna 2 tablets bid
  • 6. Tylenol 650mg tid

Added:

  • 1. Warfarin
  • 2. Citalopram 20mg daily
  • 3. PEG 3350 17g daily prn
  • 4. Vitamin D 1000IU daily
slide-54
SLIDE 54

The Case of Ed

  • 1. ASA 81 mg daily
  • 10. Multivitamin daily
  • 2. HCTZ 12.5mg daily
  • 11. Mg supplement daily
  • 3. Candesartan/HCTZ 16/12.5mg daily 12. Senna 2-4 tablets qhs
  • 4. Simvastatin 40mg daily
  • 13. Lorazepam 2mg po qid
  • 5. Solifenacin 10mg daily
  • 14. Pregabalin 75mg qhs
  • 6. Omega 3 1000mg tid
  • 15. Tylenol 650mg tid prn
  • 7. Docusate sodium 100mg bid
  • 16. Ranitidine 150mg bid
  • 8. Insulin NPH 16u qhs
  • 17. Pantoprazole 40mg daily
  • 9. Insulin R 22u breakfast, 9u lunch,

14u supper

  • 18. Folic Acid 1mg daily
slide-55
SLIDE 55

The Case of Ed

  • 1. Candesartan/HCTZ 16/12.5mg daily
  • 2. Simvastatin 40mg daily
  • 3. Insulin NPH 12u qhs
  • 4. Insulin R 18u breakfast, 5u lunch, 10u supper
  • 5. Senna 2 tablets bid
  • 6. Tylenol 650mg tid
  • 7. Warfarin
  • 8. Citalopram 20mg daily
  • 9. PEG 3350 17g daily prn
  • 10. Vitamin D 1000IU daily
slide-56
SLIDE 56

The Case of Ed

slide-57
SLIDE 57

The Case of Ed

slide-58
SLIDE 58

Falls

“Unintentionally coming to rest on the ground, floor, or other lower surface, with or without injury”.

Canadian Falls Prevention Curriculum, 2007

slide-59
SLIDE 59

Falls

  • Major source of morbidity

– Leading cause of injury in seniors

  • >85% injury related hospitalizations

– Leading cause of injury during healthcare provision

  • Major source of mortality

– Leading cause of death due to injury

slide-60
SLIDE 60

Falls

  • Avg cost of dialysis per year

– $40 000

  • Avg cost hospitalization for CABG

– $10 000

  • Avg cost of hospitalization for fall

– $30 000

slide-61
SLIDE 61

Falls Risk Factors

balance problem gait impairment muscle weakness joint problem ↓ leg sensation foot problem (any)

  • rthostasis

urinary urgency medications* age >80 female gender past hx falls cognitive impairment Parkinson’s prior stroke depression vision impairment

slide-62
SLIDE 62

balance problem gait impairment muscle weakness joint problem ↓ leg sensation foot problem (any)

  • rthostasis

urinary urgency medications* age >80 female gender past hx falls cognitive impairment Parkinson’s prior stroke depression vision impairment

poor lighting inappropriate footwear/ clothing slippery/ uneven surfaces clutter wrong/misused assistive device pets

slide-63
SLIDE 63

 Dr. P. Feltmate

slide-64
SLIDE 64

Risk Factors Chronic Falls Acute Falls medical illness

slide-65
SLIDE 65

Falls

Practical approach for the internist: STEP 1: Case find! STEP 2: Assessment STEP 3: Management

slide-66
SLIDE 66

Case Find

STEP 1: Case find! Ask the following (YEARLY)

  • 1. Fall within past year?
  • If so, how many?
  • 2. Associated injury?
  • 3. Difficulty with mobility/balance?
slide-67
SLIDE 67

Falls

STEP 2: Assessment

  • Any one fall usually happens for more than
  • ne reason

“Multifactorial risk factor model”

slide-68
SLIDE 68

Falls: Assessment

Detailed history of falls themselves

  • Frequency/Number

– One fall = increased risk more falls2

  • Witnessed vs unwitnessed
  • Associated symptoms before/during/after

– Dizziness, presyncope/syncope, palpitations

  • Injuries/consequences
  • Acute vs chronic

– If acute: health/med changes?

slide-69
SLIDE 69

Falls: Assessment

Patient history

  • Past medical history

– Visual impairment, MSK, cardiac, neuro (cognitive impairment, movement disorders, sensory impairment)

  • Functional inquiry

– IADL & ADL (difficulty with ADLs = risk falls) – Gait/balance/mobility

  • Social history

– ETOH, other rec drugs

  • Home Environment (indoors AND outdoors)

– Environmental hazards: rugs, bathroom equipment, lighting, rails, clutter, wet surfaces, gait aids

slide-70
SLIDE 70

Falls: Assessment

Medication history

“Even if the meds are stable, the patient may not be.”

slide-71
SLIDE 71

Woolcott et al (2009)

slide-72
SLIDE 72

Falls: Assessment

Physical exam

  • Vital signs

– Lying to standing HR & BP

  • Don’t forget the neuro exam!
  • Legs, feet & footwear
  • Gait, balance & mobility
  • Cognitive testing
slide-73
SLIDE 73

Falls: Assessment

Gait & balance exam

  • General observation

– Using patient’s own gait aid

  • Objective ‘in office’ measures

– Timed Up and Go (TUG)

  • Rise from chair  walk 3 m  turn  return to seated
  • Normal < 10 sec
  • ≥ 14 sec assoc. with increased falls risk
slide-74
SLIDE 74

Falls: Assessment

Investigations

  • No investigations (labs or imaging) are

routinely recommended for falls assessment

  • Acute falls = atypical presentation of illness

– Choose investigations appropriately

slide-75
SLIDE 75

Falls

Practical tips for the internist:

  • Review medications
  • Check postural v/s
  • Detailed physical exam (neuro!)
  • Important to try and treat the falls, but also

the consequences of the falls

– Vit D, calcium, bisphosphonate – PT, OT home assessment, exercise Rx

slide-76
SLIDE 76

Multifactorial Risk Factor Model

Vision impairment ↓ Mobility/balance/strength Joint & foot problems Medications Orthostatic hypotension

Vision correction Cataract extraction Exercise, PT

balance, strength, gait

↓ psychoactive meds ↓ total # meds Behavioural strategies Compression stockings Foot care

Neurologic disease

Optimize medical management

slide-77
SLIDE 77

Falls

What about single interventions?

  • May be appropriate for those at lower risk
  • Single intervention addresses one risk factor

What is the single intervention of choice?

slide-78
SLIDE 78

Falls

  • EXERCISE!
  • 2 major components: leg strengthening, balance

exercise

  • 3 approaches in RCTs:

(1) Home exercise 30min 3x weekly (2) Group exercise 1h, 1-2x weekly (3) Group exercise Tai Chi 1h 2x weekly

slide-79
SLIDE 79

Audience Poll

Q: True or false? Use of physical restrains reduce fall injuries in hospital.

slide-80
SLIDE 80

Falls

Helpful web resources

  • http://stopfalls.org
  • http://profound.eu.com
  • www.cdc.gov

– “STEADI”

slide-81
SLIDE 81